The WID-qEC test, a three-marker test that appraises DNA methylation in the gene regions of GYPC and ZSCAN12 has been shown to outperform the transvaginal ultrasound measurement of endometrial thickness in the diagnosis of endometrial cancer (AUC WID-qEC 0.94 vs. ET measurement 0.87) among women with abnormal uterine bleeding [57]. The gene discussed is GYPC; the disease is endometrial cancer.